Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Reduced Left Atrial Rotational Flow Is Independently Associated With Embolic Brain Infarcts.

Spartera M. et al, (2023), JACC Cardiovasc Imaging

Decoding the radiomic and proteomic phenotype of epicardial adipose tissue associated with adverse left atrial remodelling and post-operative atrial fibrillation in aortic stenosis.

Mancio J. et al, (2022), Eur Heart J Cardiovasc Imaging, 23, 1248 - 1259

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2022)

Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2022)

REDUCED LEFT ATRIAL ROTATIONAL FLOW IS INDEPENDENTLY ASSOCIATED WITH THE RISK OF EMBOLIC BRAIN INFARCTS

Spartera M. et al, (2022), HEART, 108, A175 - A177

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), The Lancet. Respiratory medicine, 9, 1419 - 1426

The impact of atrial fibrillation and stroke risk factors on left atrial blood flow characteristics.

Spartera M. et al, (2021), Eur Heart J Cardiovasc Imaging

The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19.

Pessoa-Amorim G. and Mafham MM., (2021), Cardiovasc Res, 117, e110 - e113

Making trials part of good clinical care: lessons from the RECOVERY trial.

Pessoa-Amorim G. et al, (2021), Future Healthc J, 8, e243 - e250

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645

Load More

Include forthcoming?